

Reference number
1860-A

## SPECIALTY GUIDELINE MANAGEMENT

### MOZOBIL (plerixafor)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication<sup>1</sup>

Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. CRITERIA FOR INITIAL APPROVAL

##### **Hematopoietic Stem Cell Mobilization (HSCs)**<sup>1-6</sup>

Authorization of 6 months may be granted for the treatment of non-Hodgkin's lymphoma (NHL) and multiple myeloma when ALL of the following criteria are met:

- A. Mozobil will be used to mobilize hematopoietic stem cells for collection prior to autologous transplantation
- B. Mozobil will be used in combination with G-CSF (e.g., filgrastim, pegfilgrastim)

##### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

##### IV. REFERENCES

1. Mozobil [package insert]. Cambridge, MA: Genzyme Corporation; December 2017.
2. The NCCN Drugs & Biologics Compendium™ © 2019 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed January 29, 2019.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Myeloid Growth Factors (Version 2.2018) <https://www.nccn.org>. Accessed January 29, 2019.
4. Micromedex® (electronic version). IBM Watson Health, Greenwood Village, Colorado. Available at <https://www.micromedexsolutions.com> [available with subscription]. Accessed January 29, 2019.
5. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [http://online.lexi.com/lco/action/doc/retrieve/docid/complete\\_ashp](http://online.lexi.com/lco/action/doc/retrieve/docid/complete_ashp) [available with subscription]. Accessed January 29, 2019.
6. Sergio G, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. *Biol Blood Marrow Transplant*. 2014; 20(3):295-308.

Reference number
1860-A

Mozobil 1860-A SGM P2019\_P.docx  
VA17JUL19P

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.